Kimio Terao

1.2k total citations · 1 hit paper
24 papers, 861 citations indexed

About

Kimio Terao is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Kimio Terao has authored 24 papers receiving a total of 861 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Hematology. Recurrent topics in Kimio Terao's work include Autoimmune and Inflammatory Disorders Research (4 papers), Pancreatic and Hepatic Oncology Research (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Kimio Terao is often cited by papers focused on Autoimmune and Inflammatory Disorders Research (4 papers), Pancreatic and Hepatic Oncology Research (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Kimio Terao collaborates with scholars based in Japan, United States and United Kingdom. Kimio Terao's co-authors include Norihiro Nishimoto, Nobuhiro Takagi, Hideko Nakahara, Toru Mima, Shuichi Mitsunaga, Atsushi Ochiai, Masatoshi Inagaki, Tomomi Tsuru, Tomohisa Saito and Masafumi Ikeda and has published in prestigious journals such as Blood, Cancer Research and Scientific Reports.

In The Last Decade

Kimio Terao

21 papers receiving 844 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

2008 587 citations Norihiro Nishimoto, Kimio Terao et al. Blood profile →

Peers

Countries citing papers authored by Kimio Terao

Since Specialization

Citations

This map shows the geographic impact of Kimio Terao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimio Terao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimio Terao more than expected).

Fields of papers citing papers by Kimio Terao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimio Terao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimio Terao. The network helps show where Kimio Terao may publish in the future.

Co-authorship network of co-authors of Kimio Terao

This figure shows the co-authorship network connecting the top 25 collaborators of Kimio Terao. A scholar is included among the top collaborators of Kimio Terao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimio Terao. Kimio Terao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Quantitative prediction of CYP2C9-mediated drug disposition using humanized mice 2025 ·Drug Metabolism and Disposition ·(unknown), (unknown), (unknown), (unknown), Tatsuhiko Tachibana, Chie Emoto, Hidetoshi Shindoh, Kimio Terao, (unknown)	0
2	Impact of the mucin barrier on the in vitro membrane permeability of cyclic peptides 2025 ·European Journal of Pharmaceutical Sciences ·(unknown), (unknown), (unknown), (unknown), Kimio Terao	0
3	Robust and reproducible human intestinal organoid-derived monolayer model for analyzing drug absorption 2025 ·Scientific Reports ·(unknown), Tatsuki Mochizuki, (unknown), Shigeto Kawai, (unknown), Tatsuhiko Tachibana, Kohsuke Uchimura, Atsuhiko Kato, (unknown), (unknown), Hiroshi Nishihara, Kimio Terao, Yasutaka Kato	1
4	Quantitative prediction of drug disposition for uridine diphosphate-glucuronosyltransferase substrates using humanized mice 2025 ·Drug Metabolism and Disposition ·(unknown), (unknown), (unknown), (unknown), Keiichi Morita, Tatsuhiko Tachibana, Kimio Terao	1
5	Quantitative prediction of CYP3A‐mediated drug–drug interactions by correctly estimating fraction metabolized using human liver chimeric mice 2023 ·British Journal of Pharmacology ·(unknown), Tatsuki Mochizuki, (unknown), Mikiko Nakamura, Chie Emoto, (unknown), (unknown), Satoshi Tsuruta, (unknown), Kimio Terao, Tatsuhiko Tachibana	8
6	Fibroblast inhibition by tocilizumab enabled gemcitabine/nab‐paclitaxel rechallenge for pancreatic cancer 2023 ·Cancer Science ·Shuichi Mitsunaga, Masafumi Ikeda, Hiroshi Imaoka, Mitsuhito Sasaki, Kazuo Watanabe, Akihiro Sato, Kazunori Aoki, Atsushi Ochiai, (unknown), (unknown), Toshihiro Yamaguchi, Kimio Terao, Noriaki Sawada, (unknown), Etsuko Fujii, Atsuhiko Kato, Hiroyuki Tsunoda	7
7	Development of rat duodenal monolayer model with effective barrier function from rat organoids for ADME assay 2023 ·Scientific Reports ·(unknown), Shigeto Kawai, Etsuko Fujii, (unknown), (unknown), (unknown), Kimio Terao, Masami Suzuki	3
8	Effects of Child-Pugh B Cirrhosis on Pharmacokinetics of Tofogliflozin, a New Sodium-Glucose Co-Transporter (SGLT2) Inhibitor 2020 ·Drug Research ·Haruki Yamada, Hiromasa Ohira, (unknown), Kōichi Nakamura, Atsushi Takahashi, Kazumichi Abe, Akihiro Inano, (unknown), (unknown), Tomohisa Saito, Yasuhiro Ohba, Kimio Terao, Akihiro Ohnishi	2
9	Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations 2019 ·The AAPS Journal ·(unknown), (unknown), Kimio Terao, Katherine L. Gill, Oliver Hatley, Iain Gardner, Neil Parrott, Patricia Sanwald Ducray	22
10	Multicenter, Open-Label, Phase I/II Study of Tocilizumab, an Anti–Interleukin-6 Receptor Monoclonal Antibody, Combined with Gemcitabine in Patients with Advanced Pancreatic Cancer 2017 ·Shuichi Mitsunaga, Takuji Okusaka, Masafumi Ikeda, Masato Ozaka, Shinichi Ohkawa, Tatsuya Ioka, (unknown), Kumi Sato, Kimio Terao, Atsushi Ochiai, Junji Furuse	6
11	Clinical pharmacology of tocilizumab for the treatment of polyarticular-course juvenile idiopathic arthritis 2017 ·Expert Review of Clinical Pharmacology ·Xiaoping Zhang, Ya‐Chi Chen, Kimio Terao	6
12	Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic‐Pharmacodynamic Modeling and Simulation 2017 ·The Journal of Clinical Pharmacology ·Tomohisa Saito, (unknown), Kimio Terao, Yuji Kumagai	7
13	Characterization of Patients With Advanced Pancreatic Cancer and High Serum Interleukin-6 Levels 2015 ·Pancreas ·Tomofumi Miura, Shuichi Mitsunaga, Masafumi Ikeda, Satoshi Shimizu, Izumi Ohno, Hideaki Takahashi, Junji Furuse, Masatoshi Inagaki, Sayumi Higashi, Hiroyuki Kato, Kimio Terao, Atsushi Ochiai	71
14	Mechanism‐based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study) 2013 ·The Journal of Clinical Pharmacology ·Shuji Ohta, Tomomi Tsuru, Kimio Terao, (unknown), (unknown), Eisuke Shono, (unknown), (unknown), Masato Imai	25
15	Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab 2013 ·Modern Rheumatology ·Tomomi Tsuru, Kimio Terao, Miho Murakami, Takaji Matsutani, (unknown), Toshiaki Amamoto, Hitoshi Nakashima, Azusa Akiyama, Norihiro Nishimoto	46
16	Associations of interleukin-6 with vegetative but not affective depressive symptoms in terminally ill cancer patients 2013 ·Supportive Care in Cancer ·Masatoshi Inagaki, Tatsuo Akechi, Toru Okuyama, Yuriko Sugawara, Hiroya Kinoshita, Yasuo Shima, Kimio Terao, Shuichi Mitsunaga, Atsushi Ochiai, Yosuke Uchitomi	20
17	Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis 2013 ·Expert Review of Clinical Pharmacology ·Xiaoping Zhang, Peter N. Morcos, Tomohisa Saito, Kimio Terao	14
18	Pharmacokinetics of eldecalcitol in primary osteoporosis patients - Randomized, double-blind, multicentre, long-term phase III clinical study 2011 ·(unknown), (unknown), Kimio Terao, Takehiko Kawanishi, (unknown), Masataka Shiraki, Toshitaka Nakamura, Toshio Matsumoto, Yusuke Tanigawara	4
19	Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease breakdown → 2008 ·Blood ·Norihiro Nishimoto, Kimio Terao, Toru Mima, Hideko Nakahara, Nobuhiro Takagi, (unknown)	587
20	Purification and Characterization of a Novel Acrosin-Like Enzyme from Boar Cauda Epididymal Sperm 1994 ·The Journal of Biochemistry ·(unknown), Kimio Terao, (unknown), (unknown), Naoto Yonezawa, Minoru Nakano, Tohru Tobita	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact